These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 20542963)

  • 21. Effectiveness of different combinations of DMARDs and glucocorticoid bridging in early rheumatoid arthritis: two-year results of CareRA.
    Stouten V; Westhovens R; Pazmino S; De Cock D; Van der Elst K; Joly J; Verschueren P;
    Rheumatology (Oxford); 2019 Dec; 58(12):2284-2294. PubMed ID: 31236568
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial.
    Bakker MF; Jacobs JW; Welsing PM; Verstappen SM; Tekstra J; Ton E; Geurts MA; van der Werf JH; van Albada-Kuipers GA; Jahangier-de Veen ZN; van der Veen MJ; Verhoef CM; Lafeber FP; Bijlsma JW;
    Ann Intern Med; 2012 Mar; 156(5):329-39. PubMed ID: 22393128
    [TBL] [Abstract][Full Text] [Related]  

  • 23. What Is the Relationship Between Morning Symptoms and Measures of Disease Activity in Patients With Rheumatoid Arthritis?
    Boers M; Buttgereit F; Saag K; Alten R; Grahn A; Storey D; Rice P; Kirwan J
    Arthritis Care Res (Hoboken); 2015 Sep; 67(9):1202-1209. PubMed ID: 25807939
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Circadian rhythms and rheumatoid arthritis.
    Cutolo M
    Joint Bone Spine; 2019 May; 86(3):327-333. PubMed ID: 30227223
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glucocorticoid use is associated with increase in HDL and no change in other lipids in rheumatoid arthritis patients.
    Schroeder LL; Tang X; Wasko MC; Bili A
    Rheumatol Int; 2015 Jun; 35(6):1059-67. PubMed ID: 25540049
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Morning glucocorticoids versus night glucocorticoids: the role of low-dose glucocorticoid chronotherapy in rheumatoid arthritis.
    Giangreco D; Cutolo M
    J Clin Rheumatol; 2014 Dec; 20(8):437-9. PubMed ID: 25417681
    [No Abstract]   [Full Text] [Related]  

  • 27. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.
    Aletaha D; Bingham CO; Tanaka Y; Agarwal P; Kurrasch R; Tak PP; Popik S
    Lancet; 2017 Mar; 389(10075):1206-1217. PubMed ID: 28215362
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Summaries for patients. Adding low-dose prednisone to methotrexate therapy for early rheumatoid arthritis.
    Ann Intern Med; 2012 Mar; 156(5):I18. PubMed ID: 22393145
    [No Abstract]   [Full Text] [Related]  

  • 29. Ask the doctor. I have rheumatoid arthritis, and my doctor wants me to take prednisone for it. Will this drug be bad for my blood pressure, which is already high?
    Shmerling RH
    Harv Heart Lett; 2010 Jul; 20(11):7. PubMed ID: 20812420
    [No Abstract]   [Full Text] [Related]  

  • 30. Chronotherapy with modified-release prednisone in patients with rheumatoid arthritis.
    Alten R
    Expert Rev Clin Immunol; 2012 Feb; 8(2):123-33. PubMed ID: 22288450
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The efficacy and safety of tocilizumab combined with disease-modifying anti-rheumatoid drugs in the treatment of active rheumatoid arthritis: a multi-center, randomized, double-blinded, placebo-controlled trial].
    Shi Q; Zhao Y; Bao CD; Li XF; Huang F; Zhu P; Li ZG; Gu JR; Zhang ZY; Zhao DB; Zhao SL; Jiang QD; Tian J; Zhang FC
    Zhonghua Nei Ke Za Zhi; 2013 Apr; 52(4):323-9. PubMed ID: 23925361
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs.
    Klareskog L; Gaubitz M; Rodriguez-Valverde V; Malaise M; Dougados M; Wajdula J;
    Ann Rheum Dis; 2006 Dec; 65(12):1578-84. PubMed ID: 16540554
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial.
    Burmester GR; Kremer JM; Van den Bosch F; Kivitz A; Bessette L; Li Y; Zhou Y; Othman AA; Pangan AL; Camp HS
    Lancet; 2018 Jun; 391(10139):2503-2512. PubMed ID: 29908669
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease-modifying antirheumatic drugs (TOPIRA): study protocol for a pragmatic trial.
    van der Leeuw MS; Welsing PMJ; de Hair MJH; Jacobs JWG; Marijnissen ACA; Linn-Rasker SP; Fodili F; Bos R; Tekstra J; van Laar JM
    Trials; 2020 Apr; 21(1):313. PubMed ID: 32248829
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study.
    Nishimoto N; Miyasaka N; Yamamoto K; Kawai S; Takeuchi T; Azuma J
    Ann Rheum Dis; 2009 Oct; 68(10):1580-4. PubMed ID: 19019888
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
    Weisman MH; Moreland LW; Furst DE; Weinblatt ME; Keystone EC; Paulus HE; Teoh LS; Velagapudi RB; Noertersheuser PA; Granneman GR; Fischkoff SA; Chartash EK
    Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.
    Bijlsma JWJ; Welsing PMJ; Woodworth TG; Middelink LM; Pethö-Schramm A; Bernasconi C; Borm MEA; Wortel CH; Ter Borg EJ; Jahangier ZN; van der Laan WH; Bruyn GAW; Baudoin P; Wijngaarden S; Vos PAJM; Bos R; Starmans MJF; Griep EN; Griep-Wentink JRM; Allaart CF; Heurkens AHM; Teitsma XM; Tekstra J; Marijnissen ACA; Lafeber FPJ; Jacobs JWG
    Lancet; 2016 Jul; 388(10042):343-355. PubMed ID: 27287832
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week-112 Efficacy and Safety Results of the Open-Label Long-Term Extension of a Phase III, Double-Blind, Randomized, Placebo-Controlled Trial.
    Bingham CO; Mendelsohn AM; Kim L; Xu Z; Leu J; Han C; Lo KH; Westhovens R; Weinblatt ME;
    Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1627-36. PubMed ID: 25623393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Delayed-release prednisone - a new approach to an old therapy.
    Buttgereit F; Gibofsky A
    Expert Opin Pharmacother; 2013 Jun; 14(8):1097-106. PubMed ID: 23594208
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term safety and effectiveness of tocilizumab in patients with rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: an open-label study close to clinical practice.
    Bykerk VP; Östör AJK; Alvaro-Gracia J; Pavelka K; Román Ivorra JA; Nurmohamed MT; Luder Y; Sidiropoulos PNM; Devenport J; Sibilia J
    Clin Rheumatol; 2019 Sep; 38(9):2411-2421. PubMed ID: 31028551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.